Polyarteritis nodosa: an evolving primary systemic vasculitis

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Matteson EL. Notes on the history of eponymic idiopathic vasculitis: the diseases of Henoch and Schonlein, Wegener, Churg and Strauss, Horton, Takayasu, Behcet, and Kawasaki. Arthritis Care Res. 2000;13(4):237–245.
   PubMed Web of Science ®Google Scholar
• Tesar V, Kazderova M, Hlavackova L. Rokitansky and his first description of polyarteritis nodosa. J Nephrol. 2004;17(1):172–174.
   PubMed Web of Science ®Google Scholar
• Matteson EL. History of vasculitis: the life and work of Adolf Kussmaul. Cleve Clin J Med. 2012;79(3):S54–6.
   PubMedGoogle Scholar
• Dickson WEC. Polyarteritis acuta nodosa and periarteritis nodosa. J Pathol Bacteriol. 1908;12(1):31–U29
   Google Scholar
• Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010;36(3):545–558.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–192.
   PubMed Web of Science ®Google Scholar
• Zetterstrom R. Nobel prize to Baruch Blumberg for the discovery of the aetiology of hepatitis B. Acta Paediatr. 2008;97(3):384–387.
   PubMed Web of Science ®Google Scholar
• Trepo C, Thivolet J. Australia antigen, virus hepatitis and periarteritis nodosa. Presse Med. 1970;78(36):1575.
   Web of Science ®Google Scholar
• Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang. 1970;19(3):410–411.
   PubMed Web of Science ®Google Scholar
• Quint L, Deny P, Guillevin L, et al. Hepatitis C virus in patients with polyarteritis nodosa. Prevalence in 38 patients. Clin Exp Rheumatol. 1991;9(3):253–257.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62(2):616–626.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–920.
   PubMed Web of Science ®Google Scholar
• Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–931.
   PubMed Web of Science ®Google Scholar
• Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum. 1995;25(1):28–34.
   PubMed Web of Science ®Google Scholar
• Selga D, Mohammad A, Sturfelt G, et al. Polyarteritis nodosa when applying the Chapel Hill nomenclature–a descriptive study on ten patients. Rheumatology (Oxford). 2006;45(10):1276–1281.
   PubMed Web of Science ®Google Scholar
• Kanecki K, Nitsch-Osuch A, Gorynski P, et al. Polyarteritis nodosa: decreasing incidence in Poland. Arch Med Sci. 2019;15(5):1308–1312.
   PubMed Web of Science ®Google Scholar
• Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–99.
   PubMed Web of Science ®Google Scholar
• Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517–522.
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Koster MJ, Crowson CS, et al. Clinical spectrum of medium-sized vessel vasculitis. Arthritis Care Res (Hoboken). 2017;69(6):884–891.
   PubMed Web of Science ®Google Scholar
• Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol. 1997;136(5):706–713.
   PubMed Web of Science ®Google Scholar
• Ebert EC, Hagspiel KD, Nagar M, et al. Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol. 2008;6(9):960–966.
   PubMed Web of Science ®Google Scholar
• Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med. 2002;112(5):386–391.
   PubMed Web of Science ®Google Scholar
• Lin YC, Kalot MA, Husainat NM, et al. Polyarteritis nodosa: a systematic review of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol. 2021;3(2):91–100.
   PubMedGoogle Scholar
• Chung SA, Gorelik M, Langford CA, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol. 2021;73(8):1384–1393.
   PubMed Web of Science ®Google Scholar
• Stanson AW, Friese JL, Johnson CM, et al. Polyarteritis nodosa: spectrum of angiographic findings. Radiographics. 2001;21(1):151–159.
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Olowofela A, Lewis B, et al. A single center 8 year experience of segmental arterial mediolysis management. Ann Vasc Surg. 2021;71:481.
   Google Scholar
• Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391(Pt 1):51–57.
   PubMed Web of Science ®Google Scholar
• Belot A, Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12(1):44.
   PubMed Web of Science ®Google Scholar
• Carmona-Rivera C, Khaznadar SS, Shwin KW, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019;134(4):395–406.
   PubMed Web of Science ®Google Scholar
• Insalaco A, Moneta GM, Pardeo M, et al. Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency. J Rheumatol. 2019;46(5):523–526.
   PubMed Web of Science ®Google Scholar
• Kendall JL, Springer JM. The many faces of a monogenic autoinflammatory disease: adenosine deaminase 2 deficiency. Curr Rheumatol Rep. 2020;22(10):64.
   PubMed Web of Science ®Google Scholar
• Springer JM, Gierer SA, Jiang H, et al. Deficiency of adenosine deaminase 2 in adult siblings: many years of a misdiagnosed disease with severe consequences. Front Immunol. 2018;9:1361.
   PubMed Web of Science ®Google Scholar
• Schnappauf O, Sampaio Moura N, Aksentijevich I, et al. Sequence-based screening of patients with idiopathic polyarteritis nodosa, granulomatosis with polyangiitis, and microscopic polyangiitis for deleterious genetic variants in ADA2. Arthritis Rheumatol. 2021;73(3):512–519.
   PubMed Web of Science ®Google Scholar
• Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43(1):8–14.
   PubMed Web of Science ®Google Scholar
• Bourgarit A, Toumelin PL, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323–330.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62(4):1186–1197.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93–100.
   PubMed Web of Science ®Google Scholar
• Chong-Neto HJ, Segundo GRS, Bandeira M, et al. Homozygous splice ADA2 gene mutation causing ADA-2 deficiency. J Clin Immunol. 2019;39(8):842–845.
   PubMed Web of Science ®Google Scholar
• Krutzke S, Horneff G. Treatment of two male children suffering from deficiency of adenosine deaminase type 2 (DADA2) with TNF-inhibitor etanercept. J Clin Rheumatol. 2021;27(8S):S509–S512.
   Web of Science ®Google Scholar
• Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380(16):1582–1584.
   PubMed Web of Science ®Google Scholar
• Chung SA, Gorelik M, Langford CA. et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol.2021;73(8):1384–1393 .
   Web of Science ®Google Scholar
• Hashem H, Kumar AR, Müller I, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682–2688.
   PubMed Web of Science ®Google Scholar